BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 20959554)

  • 21. Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.
    Filippone A; Blakeborough A; Breuer J; Grazioli L; Gschwend S; Hammerstingl R; Heinz-Peer G; Kittner T; Laghi A; Leen E; Lencioni R; Lucidarme O; Remplik P; Robinson PJ; Ruehm SG; Schaefer F; Stoupis C; Tombach B; Valette PJ; Zech CJ; Huppertz A
    J Magn Reson Imaging; 2010 Feb; 31(2):356-64. PubMed ID: 20099349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison between areas with Gd-EOB-DTPA uptake and without in hepatocellular carcinomas on Gd-EOB-DTPA-enhanced hepatobiliary-phase MR imaging: pathological correlation.
    Lee S; Kim SH; Park CK; Kim YS; Lee WJ; Lim HK
    J Magn Reson Imaging; 2010 Sep; 32(3):719-25. PubMed ID: 20815073
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gadoxetic acid-enhanced magnetic resonance imaging for differentiating small hepatocellular carcinomas (< or =2 cm in diameter) from arterial enhancing pseudolesions: special emphasis on hepatobiliary phase imaging.
    Sun HY; Lee JM; Shin CI; Lee DH; Moon SK; Kim KW; Han JK; Choi BI
    Invest Radiol; 2010 Feb; 45(2):96-103. PubMed ID: 20057319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.
    Kitao A; Zen Y; Matsui O; Gabata T; Kobayashi S; Koda W; Kozaka K; Yoneda N; Yamashita T; Kaneko S; Nakanuma Y
    Radiology; 2010 Sep; 256(3):817-26. PubMed ID: 20663969
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatic hemangiomas: difference in enhancement pattern on 3T MR imaging with gadobenate dimeglumine versus gadoxetate disodium.
    Gupta RT; Marin D; Boll DT; Husarik DB; Davis DE; Feuerlein S; Merkle EM
    Eur J Radiol; 2012 Oct; 81(10):2457-62. PubMed ID: 22138122
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
    Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
    Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Contrast enhanced MR-guided biopsy of hepatocellular carcinoma.
    König CW; Trübenbach J; Fritz J; Lauer UM; Claussen CD; Pereira PL
    Abdom Imaging; 2004; 29(1):71-6. PubMed ID: 15160756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hepatocellular carcinoma lesion characterization: single-institution clinical performance review of multiphase gadolinium-enhanced MR imaging--comparison to prior same-center results after MR systems improvements.
    Becker-Weidman DJ; Kalb B; Sharma P; Kitajima HD; Lurie CR; Chen Z; Spivey JR; Knechtle SJ; Hanish SI; Adsay NV; Farris AB; Martin DR
    Radiology; 2011 Dec; 261(3):824-33. PubMed ID: 21969663
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic kinetics of MRI contrast agents in the isolated perfused rat liver.
    Pastor CM; Terrier F; Vallée JP
    Acad Radiol; 2002 Aug; 9 Suppl 2():S455-6. PubMed ID: 12188306
    [No Abstract]   [Full Text] [Related]  

  • 32. Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.
    Marin D; Di Martino M; Guerrisi A; De Filippis G; Rossi M; Ginanni Corradini S; Masciangelo R; Catalano C; Passariello R
    Radiology; 2009 Apr; 251(1):85-95. PubMed ID: 19332848
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Capsule of hepatocellular carcinoma: where and how does the capsule show enhancement?
    Itai Y
    Radiology; 1999 Feb; 210(2):577-9. PubMed ID: 10207449
    [No Abstract]   [Full Text] [Related]  

  • 34. Gadoxetic acid disodium-enhanced magnetic resonance imaging for biliary and vascular evaluations in preoperative living liver donors: comparison with gadobenate dimeglumine-enhanced MRI.
    Lee MS; Lee JY; Kim SH; Park HS; Kim SH; Lee JM; Han JK; Choi BI
    J Magn Reson Imaging; 2011 Jan; 33(1):149-59. PubMed ID: 21182133
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
    Giovagnoni A; Paci E
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatocellular MR contrast agents: enhancement characteristics of liver parenchyma and portal vein after administration of gadoxetic acid in comparison to gadobenate dimeglumine.
    Feuerlein S; Gupta RT; Boll DT; Merkle EM
    Eur J Radiol; 2012 Sep; 81(9):2037-41. PubMed ID: 21719224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Outcomes of patients with elevated α-fetoprotein level and initial negative findings at MR imaging.
    Kim BS; Hayashi PH; Kim SH; Angthong W; Srirattanapong S; Woosley JT; Semelka RC
    Radiology; 2013 Jul; 268(1):109-19. PubMed ID: 23392426
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of cirrhotic nodules with gadoxetic acid-enhanced magnetic resonance imaging: the efficacy of hepatocyte-phase imaging.
    Chou CT; Chen YL; Su WW; Wu HK; Chen RC
    J Magn Reson Imaging; 2010 Oct; 32(4):895-902. PubMed ID: 20882620
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hepatobiliary MR imaging with gadolinium-based contrast agents.
    Frydrychowicz A; Lubner MG; Brown JJ; Merkle EM; Nagle SK; Rofsky NM; Reeder SB
    J Magn Reson Imaging; 2012 Mar; 35(3):492-511. PubMed ID: 22334493
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI.
    Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW
    AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.